These new areas of interest belong to the so-called “non-coding” genome—the 98 percent of the genome that doesn’t directly code for proteins but instead regulates how key proteins are produced.
A team from The Scripps Research Institute (TSRI) has revealed that by crossing two species of flies, they can use what they learn from the proteome of the hybrid offspring to find new clues about how proteins interact with each other
Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties.
A study from scientists at The Scripps Research Institute (TSRI) explains why the risk of osteoarthritis increases as we age and offers a potential avenue for developing new therapies to maintain healthy joints.
Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug.
Understanding how the dynein-dynactin complex is assembled and organized provides a critical foundation to explain the underlying causes of several dynein-related neurodegenerative diseases.
Researchers from the Scripps Translational Science Institute (STSI) at The Scripps Research Institute (TSRI) have launched an open-access, peer-reviewed online journal—npj Digital Medicine.
Scientists from The Scripps Research Institute have discovered that two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer.
Scientists at The Scripps Research Institute have discovered the workings of the first promising treatment for Marburg virus, a pathogen with the same pandemic potential as Ebola virus.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have now uncovered new insights into the regulatory network behind neuron growth.
Jeffery Kelly, Ph.D., co-chair of the Department of Molecular Medicine at The Scripps Research Institute (TSRI), has been named a fellow of the esteemed National Academy of Inventors (NAI), the organization announced today.
A team of researchers from The Scripps Research Institute (TSRI) and Duke University has made the first determination of the atomic structure of Transient Receptor Potential Melastatin 8 (TRPM8), a molecular sensor in nerve ends that detects cold temperatures as well as menthol and other chemicals that induce cold sensations.
This “semi-synthetic” strain of E. coli is the first to both contain unnatural bases in its DNA and use the bases to instruct cells to make a new protein.
Understanding how brains actively erase memories may open new understanding of memory loss and aging, and open the possibility of new treatments for neurodegenerative disease.
A new study from The Scripps Research Institute (TSRI) is the first to show precisely how a process in nerve cells called the S-nitrosylation (SNO) reaction—which can be caused by aging, pesticides and pollution—may contribute to Parkinson’s disease.
Celgene Corporation recently announced results from two phase 3 trials evaluating the efficacy and safety of the drug ozanimod. Ozanimod was invented by scientists at The Scripps Research Institute (TSRI).
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a molecular model that may provide a new framework for improving the design of osteoporosis treatments.
A new study from scientists on the Florida campus of The Scripps Research Institute (TSRI) offers important insights into possible links between sleep and hunger.
Chemists at The Scripps Research Institute (TSRI) have demonstrate that they can repurpose DNA to create new substances with possible medical applications.
Scientists on the Florida campus of The Scripps Research Institute (TSRI) have improved a state-of-the-art gene-editing technology to advance the system’s ability to target, cut and paste genes within human and animal cells—and broadening the ways the CRISPR-Cpf1 editing system may be used to study and fight human diseases.
Professor Matthew Disney of the Department of Chemistry on the Florida campus of The Scripps Research Institute (TSRI), together with scientists from Mayo Clinic’s Florida campus and Johns Hopkins School of Medicine, has been awarded $7.2 million from the National Institute of Neurological Disorders and Stroke of The National Institutes of Health to create new RNA-based treatments for the most common form of amyotrophic lateral sclerosis (ALS), as well as a type of frontotemporal dementia (FTD).